Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Breast Cancer

Free Subscription 27.04.2026 1 Am J Pathol 1 Am J Surg 1 Ann Oncol 3 Ann Surg Oncol 5 BMC Cancer 1 Br J Cancer 5 Breast Cancer (Dove Med Press) 2 Breast Cancer Res 2 Breast Cancer Res Treat 2 Breast J 2 Cancer 2 Cancer Res 1 Curr Treat Options Oncol 1 Eur J Surg Oncol 1 Eur Radiol 2 Int J Cancer 1 Int J Oncol 2 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 2 J Natl Cancer Inst 1 J Pathol 3 J Surg Oncol 1 Mod Pathol 1 NPJ Breast Cancer 1 Radiol Imaging Cancer 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. OGONY JW, Cruz-Reyes N, Pacheco-Spann L, Arnold A, et al
   Epidermal Growth Factor Receptor/KIT-Linked Proliferative Bias in Normal Breast Lobules from Matched Non-Hispanic Black and White Women Is Rapidly Reversible by Receptor Tyrosine Kinase Inhibition.
   Am J Pathol. 2026;196:1133-1146.
   PubMed         Abstract available
   
   

   
   Am J Surg

2. YOSHIDA CT, Higgins MG, Leslie SE, Durden JA, et al
   Patient-reported outcomes and attitudes in patients at high-risk for breast cancer.
   Am J Surg. 2026 Apr 9:116979. doi: 10.1016/j.amjsurg.2026.116979.
   PubMed         Abstract available
   
   

   
   Ann Oncol

3. WANG Y, Drubay D, Jonas SF, Dixon-Douglas J, et al
   Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.
   Ann Oncol. 2026 Apr 21:S0923-7534(26)00152-3. doi: 10.1016/j.annonc.2026.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

4. CHEN JH, Wanis KN, Rahman M, Gianchandani A, et al
   ASO Visual Abstract: Implications for Sentinel Lymph Node Biopsy Omission in Patients with Early Stage Node-Negative HR+/HER2- Breast Cancer Undergoing Mastectomy.
   Ann Surg Oncol. 2026 Apr 22. doi: 10.1245/s10434-026-19661.
   PubMed        
   
   
5. SARIDEMIR S, Guler OC, Dincer B, Karayigit A, et al
   Axillary Pathologic Complete Response as a Stronger Prognostic Marker than Breast pCR in Clinically Node-Positive Stage II-III Breast Cancer.
   Ann Surg Oncol. 2026 Apr 19. doi: 10.1245/s10434-026-19630.
   PubMed         Abstract available
   
   
6. LEE YR, Giannakeas V, Narod SA, Lim DW, et al
   Association Between Tumor Size and Nodal Positivity for HER2+ and Triple-Negative Early-Stage Breast Cancer: A Population-Based Study.
   Ann Surg Oncol. 2026 Apr 19. doi: 10.1245/s10434-026-19581.
   PubMed         Abstract available
   
   

   
   BMC Cancer

7. ZHOU Y, Wang X, Li F, Qin H, et al
   MRI quantification of intratumoral heterogeneity for predicting HER2-positive status in breast cancer: a retrospective multicenter study.
   BMC Cancer. 2026 Apr 22. doi: 10.1186/s12885-026-15956.
   PubMed        
   
   
8. LIM MSH, Tan SSN, Wan Maharuddin IB, Wan Ali SAB, et al
   Breast cancer survival rates in Sarawak, Malaysia: a central referral centre study.
   BMC Cancer. 2026 Apr 21. doi: 10.1186/s12885-026-16065.
   PubMed        
   
   
9. MATKOWSKI R, Abrahamowska M, Michalowska D, Chrusciel A, et al
   Prevalence of recurrent and non-recurrent BRCA1 and BRCA2 pathogenic variants in Polish breast cancer patients: insights from a regional genetic testing cohort from Lower Silesia.
   BMC Cancer. 2026 Apr 21. doi: 10.1186/s12885-026-16017.
   PubMed        
   
   
10. YANG X, Hao Z, Yao R, Zhang J, et al
    High TLG measured by PET/CT is associated with worse PFS in patients with advanced HR+ breast cancer treated by abemaciclib combined with endocrine therapy.
    BMC Cancer. 2026 Apr 20. doi: 10.1186/s12885-026-16032.
    PubMed        
    
    
11. XIANG Z, Qi X, Liu Y, Zhang F, et al
    Efficacy and safety of ultra-hypofractionated post-operative radiation therapy for breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026 Apr 18. doi: 10.1186/s12885-026-16020.
    PubMed        
    
    

    
    Br J Cancer

12. AHMAD S, Butle A, Karn A, Sunder R, et al
    CDKN1B inactivation impacts ER signaling and drives resistance to endocrine therapy in breast cancer.
    Br J Cancer. 2026 Apr 22. doi: 10.1038/s41416-026-03388.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

13. BIRSIN Z, Guren AK, Aliyev V, Guliyev M, et al
    Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study.
    Breast Cancer (Dove Med Press). 2026;18:598598.
    PubMed         Abstract available
    
    
14. TSUNODA A, Mizuno T, Nakamori S, Ichikawa M, et al
    Adjuvant Weekly Paclitaxel and Trastuzumab for HER2-Positive Early-Stage Breast Cancer with Preserved Baseline LVEF: Incidence of Cardiotoxicity and Feasibility of Simplified Cardiac Surveillance.
    Breast Cancer (Dove Med Press). 2026;18:596107.
    PubMed         Abstract available
    
    
15. BEHAR J, Shiang C, Dolcen DN, Bennett LB, et al
    Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression.
    Breast Cancer (Dove Med Press). 2026;18:569936.
    PubMed         Abstract available
    
    
16. MANGONE L, Marinelli F, Bisceglia I, Braghiroli MB, et al
    From Axillary Lymph Node Dissection to Sentinel Node Biopsy in Breast Cancer: A 23-Year Population-Based Large-Sample Study with Long-Term Survival Outcomes.
    Breast Cancer (Dove Med Press). 2026;18:573154.
    PubMed         Abstract available
    
    
17. XIONG M, Yang Q, Cheng L, Yu L, et al
    LINC01128 Affects Triple-Negative Breast Cancer Progression Through Targeting miR-32-5p.
    Breast Cancer (Dove Med Press). 2026;18:596228.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

18. FAN Y, Zhao Y, Zhang H, Ma T, et al
    Bio-magnetic nanomedicine for targeted drug delivery of breast cancer: green synthesis, functional design, and translational challenges.
    Breast Cancer Res. 2026 Apr 19. doi: 10.1186/s13058-026-02278.
    PubMed         Abstract available
    
    
19. ZHOU L, Ruan M, Wu J, Wu Q, et al
    The absence of B7-H4 inhibits PD-L1 expression by driving a methylation of PD-L1 promoter in breast cancer cells.
    Breast Cancer Res. 2026 Apr 22. doi: 10.1186/s13058-026-02289.
    PubMed        
    
    

    
    Breast Cancer Res Treat

20. PATHMARAJAH T, Gokun Y, Williams N, Sizemore GM, et al
    Radiation treatment patterns for breast cancer brain metastases: an NCDB analysis.
    Breast Cancer Res Treat. 2026;217:26.
    PubMed         Abstract available
    
    
21. SCHUSTER CR, Aslami ZV, Taccheri C, Azizi A, et al
    Preoperative breast cancer screening before chest masculinization surgery.
    Breast Cancer Res Treat. 2026;217:27.
    PubMed         Abstract available
    
    

    
    Breast J

22. ZHU ZM, Hu L, Ma YW, Zhu QN, et al
    Integrin Beta 4 Protein Expression Bimodally Predicts Sensitivity to CDK4/6 Inhibition and Resistance to Immunotherapy in Breast Cancer.
    Breast J. 2026;2026:e7668096.
    PubMed         Abstract available
    
    
23. WANG Z, Deng L, Wang P, Zhang Y, et al
    A Cohort Study on Cardiovascular Disease Mortality in Breast Cancer Patients With Different Subtypes.
    Breast J. 2026;2026:e8076118.
    PubMed         Abstract available
    
    

    
    Cancer

24. LAWRENCE L
    Risk-based breast cancer screening noninferior to annual screening.
    Cancer. 2026;132:e70357.
    PubMed        
    
    
25. NWIGWE I, Tenkasi RV, Desjardins MR, Visvanathan K, et al
    Poverty in the residential and surrounding counties and its impact on mortality in women with breast cancer.
    Cancer. 2026;132:e70414.
    PubMed         Abstract available
    
    

    
    Cancer Res

26. SHER EF, Fujihara KM, Tao A, Sastourne-Haletou P, et al
    Targeting DNA Polymerase Epsilon Induces Tumor Clearance and Activates an NF-kappaB-Mediated Inflammatory Response in Triple Negative Breast Cancer.
    Cancer Res. 2026 Apr 21. doi: 10.1158/0008-5472.CAN-25-2217.
    PubMed         Abstract available
    
    
27. YOUNG RG, Esquea EM, Ciraku L, Merzy J, et al
    ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis.
    Cancer Res. 2026 Apr 22. doi: 10.1158/0008-5472.CAN-25-3006.
    PubMed         Abstract available
    
    

    
    Curr Treat Options Oncol

28. CETIN B, Erdem D, Karaman I, Gumusay O, et al
    Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer.
    Curr Treat Options Oncol. 2026;27:21.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

29. CLAASSENS EL, Koppert LB, van der Pol CC, Luiten EJT, et al
    Impact of less invasive axillary staging procedures after neoadjuvant systemic therapy on adjuvant systemic therapy indications in HER2-positive and triple-negative breast cancer.
    Eur J Surg Oncol. 2026;52:111785.
    PubMed         Abstract available
    
    

    
    Eur Radiol

30. MAO K, Li Z, Li J, Xie Y, et al
    Mammography-based artificial intelligence model for predicting axillary lymph node status after neoadjuvant therapy in breast cancer.
    Eur Radiol. 2026 Apr 18. doi: 10.1007/s00330-026-12526.
    PubMed         Abstract available
    
    

    
    Int J Cancer

31. MITRA PR, Bertrand KA, Pfeiffer RM, Palmer JR, et al
    Prenatal diethylstilbestrol exposure and risk of benign breast disease: The National Cancer Institute Diethylstilbestrol Follow-up Study.
    Int J Cancer. 2026;158:3101-3111.
    PubMed         Abstract available
    
    
32. PANTELAIOU-PROKAKI G, Bamahmoud H, Georges NS, Jansari S, et al
    MUC1 as a Survival Effector of Radiotherapy-Induced Epithelial Hybrid States in Basal-Like Breast Cancer.
    Int J Cancer. 2026 Apr 18. doi: 10.1002/ijc.70487.
    PubMed         Abstract available
    
    

    
    Int J Oncol

33. CHU L, Xiao Y, Li X, Cui J, et al
    Research advances in aptamers in the diagnosis and treatment of breast cancer (Review).
    Int J Oncol. 2026;68:72.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

34. HELOU J, Glicksman R, Bezjak A, Raman S, et al
    Health-Related Quality of Life After SBRT for Oligoprogressive Disease: Results From a Phase II Prospective Trial.
    Int J Radiat Oncol Biol Phys. 2026;125:348-357.
    PubMed         Abstract available
    
    
35. LECLERC C, Baker S, Jiang W, Mou B, et al
    Treatment With Stereotactic Ablative Radiation Therapy for Patients With up to 5 Oligometastatic Cancer Lesions: Long-Term Outcomes of the Nonrandomized Population-based Phase 2 SABR-5 Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2026;125:330-337.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

36. LOIBL S, Untch M, Huober J, Schaser V, et al
    Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial.
    J Clin Oncol. 2026 Apr 20:JCO2502311. doi: 10.1200/JCO-25-02311.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

37. SPOOR J, Mureau MAM, de Jong D, Tissier RLM, et al
    Risk of autoimmune and rheumatic diseases in breast cancer patients with silicone breast implants.
    J Natl Cancer Inst. 2026 Apr 19:djag115. doi: 10.1093.
    PubMed         Abstract available
    
    
38. O'CONNELL CP, Burns KF, Hong HG, Kahle L, et al
    Title: Ultra-processed food intake and postmenopausal breast cancer risk in the NIH-AARP diet and health study.
    J Natl Cancer Inst. 2026 Apr 21:djag124. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Pathol

39. LLEWELLYN AM, D'Costa SL, Lam CY, Gore JA, et al
    Topological analysis of the human lymph node reticular network predicts outcome in breast cancer.
    J Pathol. 2026 Apr 20. doi: 10.1002/path.70065.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

40. BIRSINE Z, Alkan O, Bukun HO, Nazli I, et al
    Does Surgical Timing After Neoadjuvant Anti-HER2 Therapy Affect Pathological Complete Response and Survival in HER2-Positive Breast Cancer? A Multicenter Retrospective Cohort Study.
    J Surg Oncol. 2026 Apr 23. doi: 10.1002/jso.70270.
    PubMed         Abstract available
    
    
41. CRONIN JE, Aryanpour Z, Durden JA, Hunt SC, et al
    Identifying Breast Cancer Risk in Patients Undergoing Gender-Affirming Chest Masculinization Surgery.
    J Surg Oncol. 2026 Apr 23. doi: 10.1002/jso.70272.
    PubMed         Abstract available
    
    
42. EL-GABALAWY R, Logan GS, Hebbard P, Sommer JL, et al
    An Interactive Preoperative Virtual Reality Intervention for Breast Cancer Patients Undergoing Oncological Surgery: A Feasibility and Pilot Randomized Clinical Trial.
    J Surg Oncol. 2026 Apr 23. doi: 10.1002/jso.70269.
    PubMed         Abstract available
    
    

    
    Mod Pathol

43. DENKERT C, Rachakonda S, Pehl A, Marme F, et al
    Clinical and Molecular Evaluation of HER2-Low and Ultralow Breast Cancer in the PENELOPE-B Clinical Trial Cohort.
    Mod Pathol. 2026 Apr 21:101006. doi: 10.1016/j.modpat.2026.101006.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

44. PETERS J, Penning de Vries BBL, van Dijck JAAM, Mann RM, et al
    Development and internal validation of mammography feature-based prognostic models for distant recurrence-free survival of invasive breast cancer in a screening cohort.
    NPJ Breast Cancer. 2026 Apr 20. doi: 10.1038/s41523-026-00946.
    PubMed         Abstract available
    
    

    
    Radiol Imaging Cancer

45. SHU C, Joe B
    Percutaneous Thermal Ablation for Early-Stage Breast Cancer: A Randomized Phase II "Pick-the-Winner" Trial.
    Radiol Imaging Cancer. 2026;8:e269008.
    PubMed        
    
    

    
    Radiother Oncol

46. RUSSELL NS, Dixon MJ, Sainsbury R, Chua B, et al
    Response to Machiels et al. reconsidering the role of PMRT in low to intermediate risk breast cancer: applying results from previous standards of treatments in the current multimodal practice, FRC.
    Radiother Oncol. 2026 Apr 20:111542. doi: 10.1016/j.radonc.2026.111542.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum